July 18th, 2012
FDA Approves Another New Weight Loss Drug
Larry Husten, PHD
The US FDA approved on Tuesday a new weight loss drug that will be called Qsymia, the brand name for the combination of two previously approved drugs, phentermine and extended-release topiramate. The drug is manufactured by Vivus, Inc. In a press release, the FDA said Qsymia had been approved for use in obese adults (BMI of 30 or […]
April 11th, 2011
Phentermine-Topiramate Combination Yields Significant Weight Loss
Larry Husten, PHD
The experimental diet drug combination of phentermine and topiramate demonstrated “robust efficacy” in CONQUER, a large new trial published online in the Lancet. The trial’s results come after a year in which the FDA turned down three investigational diet drugs (including Qnexa, the phentermine-topiramate combination used here) and removed the diet drug sibutramine from the […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?